WE MOVE
204 West 84th Street
New York, NY 10024
E-mail: wemove@wemove.org
wemove.org • mdvu.org
Stay Connected Research News Chat Discussion Forum Advocacy and Support Organizations Patient Meeting Calendar Movement Disorder Glossary Movement Disorders Virtual University Linkage Library
WE MOVE

Make a Donation
Ataxia
Bradykinesia
Choreoathetosis
Corticobasal Degeneration
Dyskinesias (Paroxysmal)
Dystonia
Essential Tremor
Hereditary Spastic Paraplegia
Huntington's Disease
Multiple System Atrophy
Myoclonus
Parkinson's Disease
Progressive Supranuclear Palsy
Restless Legs Syndrome
Rett Syndrome
Spasticity
Sydenham's Chorea
Tardive Dyskinesia
Tics
Tourette's Syndrome
Tremor
Wilson Disease
 

E-MOVE Research News

Subject: Tetrabenazine for Huntington's Disease (AAN 2001)

Date: 5/8/2001

E-MOVE reports from the 53rd Annual Meeting of the American Academy of Neurology in Philadelphia May 5-11, 2001. Poster and Platform session numbers refer to abstracts published in Neurology 2001;56 (Supplement 3). 
 
P01.012 Tetrabenazine for Huntington's disease chorea: A single-blind study 
WG Ondo, R Tintner, C Kwak, M Thomas, J Jankovic 
 
Tetrabenazine can improve chorea in HD for up to a year, according to this study. Twelve patients (mean age 58) received tetrabenazine for 4-12 months (mean dose 66 mg/day). Abnormal Involuntary Movement Scale scores rated by a blinded investigator decreased from 17.0 to 13.5 (p=0.02). Other features of the disorder were not affected. Adverse effects included akathisia, constipation, drooling, and insomnia, most of which resolved with dose adjustment.